Dr. Saygin’s laboratory investigates the biology of leukemia using both in vitro and in vivo models of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), as well as human samples from patients with these malignancies. A key focus of the lab is understanding the drivers of clonal hematopoiesis of indeterminate potential (CHIP) and its progression to leukemias of either myeloid or lymphoid lineage, in both de novo and therapy-related contexts.
The overarching goal of Dr. Saygin’s translational research program is to identify the molecular and cellular mechanisms that drive these fatal diseases and to translate those insights into novel therapeutic strategies. The lab’s drug development efforts are particularly focused on high-risk subsets of AML and ALL and have resulted in the launch of investigator-initiated phase I/II clinical trials originating directly from discoveries made in the lab.
Outcomes of patients with relapsed/refractory acute leukaemia treated with revumenib with a focus on post-revumenib therapies.
Outcomes of patients with relapsed/refractory acute leukaemia treated with revumenib with a focus on post-revumenib therapies. Br J Haematol. 2026 Jan; 208(1):343-347.
PMID: 41139955
CCRL2 and who? An important driver in TP53-mutant myeloid leukemias.
CCRL2 and who? An important driver in TP53-mutant myeloid leukemias. Haematologica. 2026 Feb 01; 111(2):442-443.
PMID: 40931868
Type 2 calreticulin mutations activate ATF6 to promote BCL-xL-mediated survival in myeloproliferative neoplasms.
Type 2 calreticulin mutations activate ATF6 to promote BCL-xL-mediated survival in myeloproliferative neoplasms. Blood. 2025 Aug 21; 146(8):971-983.
PMID: 40403318
Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults.
Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults. Blood Cancer J. 2025 Aug 14; 15(1):138.
PMID: 40813576
Factors associated with survival after allogeneic transplantation for myeloid neoplasms harboring TP53 mutations.
Factors associated with survival after allogeneic transplantation for myeloid neoplasms harboring TP53 mutations. Blood Adv. 2025 Jul 22; 9(14):3395-3407.
PMID: 40085959
Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma.
Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma. Leukemia. 2025 Sep; 39(9):2285-2288.
PMID: 40670674
Outcomes for Patients With Myeloid Neoplasms Treated With Chemotherapy Plus Venetoclax After Prior Venetoclax Therapy.
Outcomes for Patients With Myeloid Neoplasms Treated With Chemotherapy Plus Venetoclax After Prior Venetoclax Therapy. EJHaem. 2025 Jun; 6(3):e70078.
PMID: 40521395
TP53 mutations and TET2 deficiency cooperate to drive leukemogenesis and establish an immunosuppressive environment.
TP53 mutations and TET2 deficiency cooperate to drive leukemogenesis and establish an immunosuppressive environment. J Clin Invest. 2025 May 15; 135(10).
PMID: 40111422
CD58 expression does not impact response to inotuzumab ozogamicin in patients with B-cell acute lymphoblastic leukemia.
CD58 expression does not impact response to inotuzumab ozogamicin in patients with B-cell acute lymphoblastic leukemia. EJHaem. 2025 Feb; 6(1):e1076.
PMID: 39866945
Risk prediction for clonal cytopenia: multicenter real-world evidence.
Risk prediction for clonal cytopenia: multicenter real-world evidence. Blood. 2024 Nov 07; 144(19):2033-2044.
PMID: 38996210